Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

The Metabolic Syndrome is Associated with More Aggressive Prostate Cancer

  • Ozbek, Emin (Okmeydani Training and Research Hospital, Department of Urology) ;
  • Otunctemur, Alper (Okmeydani Training and Research Hospital, Department of Urology) ;
  • Dursun, Murat (Bahcelievler State Hospital, Department of Urology) ;
  • Sahin, Suleyman (Okmeydani Training and Research Hospital, Department of Urology) ;
  • Besiroglu, Huseyin (Okmeydani Training and Research Hospital, Department of Urology) ;
  • Koklu, Ismail (Okmeydani Training and Research Hospital, Department of Urology) ;
  • Erkoc, Mustafa (Okmeydani Training and Research Hospital, Department of Urology) ;
  • Danis, Eyyup (Okmeydani Training and Research Hospital, Department of Urology) ;
  • Bozkurt, Muammer (Okmeydani Training and Research Hospital, Department of Urology)
  • Published : 2014.05.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The aim of this study was to analyze any association between the metabolic syndrome (MetS) and risk of prostate cancer (PCa) and cancer grade among men undergoing radical prostatectomy for PCa. Materials and Methods: 50 patients with MetS and 50 patients without MetS who undervent radical prostatectomy (RP) were included in the study. Age at biopsy, height, weight, digital rectal examination (DRE), pre-biopsy PSA levels, prostate volume, histopathologic diagnosis after surgery and gleason scores were collected data from all patients. Histologic material obtained at biopsy was given a Gleason score; tumours with a Gleason score ${\geq}7$ were considered high grade and <7 were considered low grade. Results: The mean age at the time of biopsy was $63.7{\pm}5.94$ in patients with MetS and $61.6{\pm}6.14$ in patients without MetS. Men with MetS had significantly lower PSA levels (p=0.01) ($7.21{\pm}2.74$ and $8.81{\pm}2.72$, respectively). Also, the men with MetS had higher RP tumor grade (p=0.04). Conclusions: Men with MetS undergoing RP have lower PSA levels and have significantly higher grade PCa. We must be careful for screening PCa in patients with MetS. Although the patients had lower PSA levels, they may have high grade disease.

Keywords

References

  1. Alberti KG, Eckel RH, Grundy SM, et al (2009). Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 120, 1640-5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644
  2. Beebe Dimmer JL, Dunn RL, Sarma AV, et al (2007). Features of the metabolic syndrome and prostate cancer in African- American men. Cancer, 109, 875-81. https://doi.org/10.1002/cncr.22461
  3. Beebe Dimmer JL, Nock NL, Neslund-Dudas C, et al (2009). Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology, 74, 185-90. https://doi.org/10.1016/j.urology.2009.03.013
  4. Buschemeyer WC III, Freedland SJ (2007). Obesity and prostate cancer: Epidemiology and clinical implications. Eur Urol, 52, 331-43. https://doi.org/10.1016/j.eururo.2007.04.069
  5. Chan JM, Stampfer MJ, Giovannucci E, et al (1998). Plasma insulin-like growth factor-I and pros- tate cancer risk: a prospective study. Science, 279, 563-6. https://doi.org/10.1126/science.279.5350.563
  6. De Nunzio C, Freeland S, Miano R, et al (2011). Meatabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy. Prostate, 71, 1492-8.
  7. Epstein JI, Allsbrook WC Jr, Amin MB, et al (2005). The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol, 29, 1228-42. https://doi.org/10.1097/01.pas.0000173646.99337.b1
  8. Guo YZ, Pan L, Du CJ, Ren DQ, Xie XM (2013). Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pac J Cancer Prev, 14, 243-8. https://doi.org/10.7314/APJCP.2013.14.1.243
  9. Hammarsten J, Hogstedt B (2004). Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press, 13, 47-55. https://doi.org/10.1080/08037050310025735
  10. Hsing AW, Sakoda LC, Chua S Jr (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr, 86, 843-57. https://doi.org/10.1093/ajcn/86.3.843S
  11. Jeon KP, Jeong TY, Lee SY, et al (2012). Prostate cancer in patients with metabolic syndrome is associated with low grade gleason score when diagnosed on biopsy. Korean J Urol, 53, 593-7. https://doi.org/10.4111/kju.2012.53.9.593
  12. Kang DI, Chung JI, Ha HK, et al (2013). Korean prostate cancer patients have worse disease characteristics than their American counterparts. Asian Pac J Cancer Prev, 14, 6913-7. https://doi.org/10.7314/APJCP.2013.14.11.6913
  13. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000). The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev, 21, 215-44. https://doi.org/10.1210/edrv.21.3.0399
  14. Kim YJ, Cho YJ, Oh JE, et al (2008). The association between metabolic syndrome and prostate-specific antigen levels. Int J Urol, 15, 905-9. https://doi.org/10.1111/j.1442-2042.2008.02137.x
  15. Kristal AR, Chi C, Tangen CM, et al (2006). Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer, 106, 320-8. https://doi.org/10.1002/cncr.21603
  16. Laukkanen JA, Laaksonen DE, Niskanen L, et al (2004). Metabolic syndrome and the risk of prostate cancer in Finnish men: a population based study. Cancer Epidemiol Biomarkers Prev, 13, 1646-50.
  17. LeRoith D, Roberts CT Jr (2003). The insulin-like growth factor system and cancer. Cancer Lett, 195, 127-37. https://doi.org/10.1016/S0304-3835(03)00159-9
  18. Long XJ, Lin S, Sun YN, Zheng ZF (2012). Diabetes mellitus and prostate cancer risk in Asian countries: a meta-analysis. Asian Pac J Cancer Prev, 13, 4097-100. https://doi.org/10.7314/APJCP.2012.13.8.4097
  19. Martin RM, Vatten L, Gunnell D, et al (2009). Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control, 20, 1181-92. https://doi.org/10.1007/s10552-009-9319-x
  20. Oliver SE, Gunnell D, Donovan J, et al (2004). Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. Int J Cancer, 108, 887-92. https://doi.org/10.1002/ijc.11631
  21. Ozbek E, Otunctemur A, Dursun M, et al (2014) Association between the Metabolic Syndrome and High Tumor Grade and Stage of Primary Urothelial Cell Carcinoma of the Bladder. Asian Pac J Cancer Prev, 15, 1447-51. https://doi.org/10.7314/APJCP.2014.15.3.1447
  22. Ozbek E, Otunctemur A, Sahin S, et al (2013). Renal cell carcinoma is more aggressive in Turkish patients with the metabolic syndrome. Asian Pac J Cancer Prev, 14, 7351-4. https://doi.org/10.7314/APJCP.2013.14.12.7351
  23. Pandeya DR, Mittal A, Sathian B, Bhatta B (2014). Role of hyperinsulinemia in increased risk of prostate cancer: a case control study from Kathmandu Valley. Asian Pac J Cancer Prev, 15, 1031-3. https://doi.org/10.7314/APJCP.2014.15.2.1031
  24. Parekh N, Lin Y, Marcella S, et al (2008). Associations of lifestyle and physiologic factors with prostate-specific antigen concentrations: evidence from the National Health and Nutrition Examination Survey (2001-2004). Cancer Epidemiol Biomarkers Prev, 17, 2467-72. https://doi.org/10.1158/1055-9965.EPI-08-0059
  25. Pelucchi C, Negri E, Talamini R, et al (2010). Metabolic syndrome is associated with colorectal cancer in men. Eur J Cancer, 46, 1866-72. https://doi.org/10.1016/j.ejca.2010.03.010
  26. Platz EA, Leitzmann MF, Rifai N, et al (2005). Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev, 14, 1262-9. https://doi.org/10.1158/1055-9965.EPI-04-0371
  27. Pothiwala P, Jain SK, Yaturu S (2009). Metabolic syndrome and cancer. Metab Syndr Relat Disord, 7, 279-88. https://doi.org/10.1089/met.2008.0065
  28. Renehan AG, Zwahlen M, Minder C, et al (2004). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet, 363, 1346-53. https://doi.org/10.1016/S0140-6736(04)16044-3
  29. Rosato V, Zucchetto A, Bosetti C, et al (2011). Metabolic syndrome and endometrial cancer risk. Ann Oncol, 22, 884-9. https://doi.org/10.1093/annonc/mdq464
  30. Rosato V, Tavani A, Bosetti C, et al (2011). Metabolic syndrome and pancreatic cancer risk: a case-control study in Italy and meta-analysis. Metabolism, 60, 1372-8. https://doi.org/10.1016/j.metabol.2011.03.005
  31. Siegel R, Ward E, Brawley O, Jemal A (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin, 61, 212-36. https://doi.org/10.3322/caac.20121
  32. Teloken C, Da Ros CT, Caraver F, et al (2005). Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol, 174, 2178-80. https://doi.org/10.1097/01.ju.0000181818.51977.29
  33. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J (2004). Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem, 266, 37-56. https://doi.org/10.1023/B:MCBI.0000049134.69131.89
  34. Werny DM, Saraiya M, Gregg EW (2006). Prostate-specific antigen values in diabetic and non-diabetic US men, 2001- 2002. Am J Epidemiol, 164, 978-83. https://doi.org/10.1093/aje/kwj311
  35. Zhou JR, Blackburn GL, Walker WA (2007). Symposium introduction: metabolic syndrome and the onset of cancer. Am J Clin Nutr, 86, 817-9. https://doi.org/10.1093/ajcn/86.3.817S

Cited by

  1. Association of Polymorphisms in Stress-Related TNFα and NPY Genes with the Metabolic Syndrome in Han and Hui Ethnic Groups vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5895
  2. Evaluation of Environmental Risk Factors for Prostate Cancer in a Population of Iranian Patients vol.15, pp.24, 2014, https://doi.org/10.7314/APJCP.2014.15.24.10603
  3. Human Kallikrein-2, Prostate Specific Antigen and Free-Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.7085
  4. Metabolic syndrome, dyslipidemia and prostate cancer recurrence after primary surgery or radiation in a veterans cohort vol.18, pp.2, 2015, https://doi.org/10.1038/pcan.2015.12
  5. Metabolic syndrome is associated with better prognosis in patients with tongue squamous cell carcinoma vol.34, pp.3, 2015, https://doi.org/10.1186/s40880-015-0009-7
  6. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study vol.16, pp.1, 2016, https://doi.org/10.1186/s12885-016-2442-7
  7. Meta-analysis of metabolic syndrome and prostate cancer vol.20, pp.2, 2017, https://doi.org/10.1038/pcan.2017.1
  8. Overexpression and knock-down studies highlight that a disintegrin and metalloproteinase 28 controls proliferation and migration in human prostate cancer vol.95, pp.40, 2016, https://doi.org/10.1097/MD.0000000000005085